2051527-54-7
Chemical Structure
DOTA-XYIMSR-01
- CAS No.: 2051527-54-7
- Formula:C61H88N16O22S2
- Molecular Weight:1461.58
InChIKey: DMAXCXQYACQFKS-OLCJBLMYSA-N
SMILES: O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(NCCOCCOCCNC([C@@H](NC(C[C@@H](C(O)=O)NC(C[C@@H](C(O)=O)NC(CCC(C)(C2=CC=C(O)C=C2)C3=CC=C(O)C=C3)=O)=O)=O)CCCCN4C=C(CCCC(NC5=NN=C(S(=O)(N)=O)S5)=O)N=N4)=O)=O)CC1
Biological Activity: DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA-XYIMSR-01 | DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
